A retrospective analysis of treatment patterns, drug discontinuation and healthcare costs in Crohn’s disease patients treated with biologics
Background/aims: This real-world analysis evaluated the persistence and direct healthcare costs of Crohn’s Disease (CD) patients treated with biologics in Italy. Methods: A retrospective analysis on administrative databases of Italian healthcare entities, covering 10.4 million residents, was performed. Adult CD patients under biologics between 2015 and 2020 were in- cluded and attributed to first/second treatment… Leggi tutto »A retrospective analysis of treatment patterns, drug discontinuation and healthcare costs in Crohn’s disease patients treated with biologics
Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy
Background: This real-world analysis evaluated drug utilization focusing on wastage and healthcare costsfor treatment of patients with advanced breast cancer (aBC) hormone receptor-positive (HR+)/humanepidermal growth factor receptor-2 negative (HER2-) in Italy.Methods: A retrospective analysis was conducted on administrative data covering about 13.3 millionhealth-assisted individuals. Across January/2017–June/2021, all patients with HR+/HER2-aBC wereidentified by ≥ 1 prescription… Leggi tutto »Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy
Real-world Evaluation of the Management, Treatment Pathways and Outcome of Melanoma Patients with Target Therapies in Italy
In recent years, an increasing trend in the incidence of melanoma has been observed in Europe. Although early diagnosis and prompt intervention with local resection often results in positive outcomes, conversely, metastatic disease is still clinically challenging with a poor prognosis and a 5-year survival of around 30%. The growing awareness of melanoma biology and… Leggi tutto »Real-world Evaluation of the Management, Treatment Pathways and Outcome of Melanoma Patients with Target Therapies in Italy
Incidence and Predictors of Switching and Dose Change of Direct Oral Anticoagulants among Elderly Patients with Nonvalvular Atrial Fibrillation: A 5-Year Analysis of a Large Administrative Database
In the last decade, novel oral anticoagulants (NOACs) have emerged as prominent therapeutic options in non-valvular atrial fibrillation (NVAF). We analysed the clinical burden and the switching rate between all available NOACs, and their dosage change over a period of 5 years in a representative population of patients with NVAF aged between 70 and 75… Leggi tutto »Incidence and Predictors of Switching and Dose Change of Direct Oral Anticoagulants among Elderly Patients with Nonvalvular Atrial Fibrillation: A 5-Year Analysis of a Large Administrative Database
Analysis of drug utilization in patients with psoriasis: a real-world retrospective study among the Italian population
Purpose: An Italian real-world retrospective study was conducted in patients with psoriasis (PSO) to evaluate their characteristics, treatment patterns, and biological/targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) drug utilization.Patients and Methods: The retrospective analysis was carried out on real-world data collected from administrative databases of selected Italian health-departments; the dataset covered approximately 22% of the Italian population. PSO… Leggi tutto »Analysis of drug utilization in patients with psoriasis: a real-world retrospective study among the Italian population
Epidemiology, Patients’ Journey and Healthcare Costs in Early-Stage Non-Small-Cell Lung Carcinoma: A Real-World Evidence Analysis in Italy
This real-world analysis aims to estimate the epidemiology and economic burden related to early-stage non-small-cell lung carcinoma (eNSCLC) in the clinical practice Italian setting. An observational analysis was performed using administrative databases linked to pathological anatomy data, covering around 2.5 mln health-assisted individuals. From 2015 to mid-2021, eNSCLC patients staged II–IIIA treated with chemotherapy after… Leggi tutto »Epidemiology, Patients’ Journey and Healthcare Costs in Early-Stage Non-Small-Cell Lung Carcinoma: A Real-World Evidence Analysis in Italy
Healthcare Resource Consumption and Related Costs in Patients on Antiretroviral Therapies: Findings from Real-World Data in Italy
This real-world analysis conducted on administrative databases of a sample of Italian healthcare entities was aimed at describing the role of therapeutic pathways and drug utilization in terms of adherence, persistence, and therapy discontinuation in HIV-infected patients under antiretroviral therapies (ART) and Tenofovir Alafenamide (TAF)-based regimens on healthcare resource consumption and related direct healthcare costs. Between 2015 and 2019, adults (≥18 years) prescribed with TAF-based therapies were identified and characterized in the year prior to the first prescription (index-date) for TAF-based therapies and followed-up until the end of data availability. Overall, 2658 ART-treated patients were included, 1198 of which were under a TAF-based regimen. TAF-based therapies were associated with elevated percentages of adherence (83.3% patients with proportion of days covered, PDC > 95% and 90.6% with PDC > 85%) and persistence (78.5%). The discontinuation rate was low in TAF-treated patients, ranging from 3.3% in TAF-switchers to 5% in naïve. Persistent patients had lower overall mean annual healthcare expenditures (EUR 11,106 in persistent vs. EUR 12,380 in non-persistent, p = 0.005), and this trend was statistically significant also for costs related to HIV hospitalizations. These findings suggest that a better therapeutic management of HIV infection might result in positive clinical and economic outcomes.
La gestione terapeutica e il burden economico dei pazienti trattati con ESA affetti da insufficienza renale cronica non dipendente da dialisi con anemia: risultati da uno studio real-world in Italia
Background. L’obiettivo dell’analisi real-world è stato valutare le caratteristiche dei pazienti con insufficienza renale cronica non dipendente da dialisi (IRC-NDD) con anemia e trattati con agenti stimolanti l’eritropoiesi (ESA), analizzarne la farmaco-utilizzazione e il carico economico in pratica clinica italiana. Metodi. È stata eseguita un’analisi retrospettiva basata su database amministrativi e di laboratorio riguardanti circa… Leggi tutto »La gestione terapeutica e il burden economico dei pazienti trattati con ESA affetti da insufficienza renale cronica non dipendente da dialisi con anemia: risultati da uno studio real-world in Italia
The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy
Introduction: Chronic myeloid leukemia (CML) is a hematopoietic myeloproliferative disorder that accounts for 20% of all leukemias of adults. The introduction of tyrosine kinase inhibitors (TKIs) (imatinib, bosutinib, dasatinib, nilotinib, ponatinib) has yielded significant benefits for patients with CML in terms of survival and quality of life. This real-world analysis evaluated the economic burden for managing… Leggi tutto »The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy